A recombinant matrix to improve autologous tissue grafts
A recombinant matrix to improve autologous tissue grafts
批准号:
10652973
负责人:
Stefan Roberts
金额:
$103.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-11 至 2024-06-30
关键词:
AddressAdipose tissueAreaAutologousAutomobile DrivingBiologicalBiological ProductsBiomechanicsBiopsyBody TemperatureBreastCancer PatientCannulasCellular InfiltrationCicatrixClinicalComplexContractsContractureCystDefectDevelopmentDevicesElastinEndotoxinsEvaluationEventExtracellular Matrix ProteinsFamily suidaeFatty acid glycerol estersFermentationFibrosisForeign BodiesFormulationFundingGeneral AnesthesiaGoalsGrantGrowthHarvestHistologicImplantInflammatory ResponseInjectableInjectionsInternal Breast ProsthesisInvestmentsKi-1 Large-Cell LymphomaLaboratoriesLength of StayLiquid substanceMammaplastyMastectomyMaterials TestingMethodsModelingMolecularMonitorMusNatural regenerationNecrosisOperative Surgical ProceduresOutcomeOutpatientsPatientsPhasePhase TransitionPolymersPorosityPreclinical TestingProceduresProcessProductionPropertyProtein EngineeringProteinsRecombinant ProteinsRecombinantsReconstructive Surgical ProceduresRecoverySafetySecond Look SurgeryShapesSiliconesSmall Business Innovation Research GrantSolidStructureSuction LipectomySurgeonTechnologyTemperatureTestingTimeTissue GraftsTissuesToxic effectTranslationsVascularizationbiomaterial compatibilityblood vessel developmentbreast lumpectomycalcificationclinical practiceclinically relevantcommercializationcomparison controlcostcytotoxicityefficacy testingfat graftingimplantationimprovedin vivoindustrial productioninnovationirritationmammarymanufacturemanufacturing organizationmanufacturing processmanufacturing scale-upmechanical propertiesphase 1 studyporcine modelprogramsreconstructionrepairedresearch clinical testingresponserestorationsafety testingscaffoldscale upsoft tissuesuccesstissue regenerationtissue repair
中文摘要
项目摘要
这项建议目的是进一步开发一种新的修复组织基质,第一阶段研究表明
能够扩大自体脂肪移植在乳房重建手术中的应用。这个目标是
其动机是需要提高癌症患者乳房再造的可及性和安全性。乳房
植入物在该领域占据主导地位,因为它们易于放置并提供定义的形状。然而,越来越多的人担心
植入物对包膜痉挛、乳房假体疾病(BII)和乳房的长期影响
植入性间变性大细胞淋巴瘤(BIA-ALCL)正促使许多患者寻求其他选择。
组织瓣手术有效地将大片脂肪输送到缺损处;然而,这些手术是
复杂、昂贵,并不是所有患者都能广泛获得。成功组织瓣的远期疗效
是有利的,但与在时间、金钱、身体伤痕和努力方面的重大投资有关。第三种选择
是自体脂肪,也可以作为移植物进行移植,只需吸脂和注射小插管
门诊手术。尽管它有潜力,但许多外科医生在使用脂肪时感到自己的能力有限
移植物:(1)通过吸脂获取脂肪会破坏其结构基质,导致不成形的泥浆,以及(2)
许多患者根本没有足够的脂肪来捐献。到目前为止,使用脂肪的技术和手术障碍
对于最终的乳房重建,移植还没有解决。虽然已经做出了改进的尝试
通过将组织与合成聚合物或脱细胞组织相结合的移植成功率,这些尝试
由于缺乏内在生物活性、成本高或加工时间长而显示出最小的成功。重组
蛋白质聚合物是一种尚未开发但很有希望的替代品,可以模仿自然产生的细胞外
通过分子水平控制基质蛋白的性质,可以高产率地合成基质蛋白。以此为动力
明确的临床需求,这项建议寻求推进最近开发的创新产品的商业化
BioMatrix-Fractomer。Fractomers是一种人造蛋白质,旨在模仿可以联合注射的软组织
利用脂肪来扩大体积,增加长期稳定性,并通过允许组织内生和改善脂肪形状
血管形成。第一阶段的计划重点是Fractomer与吸脂剂的相互作用,以确定
生物力学和热响应特性非常适合组织修复基质。体内研究
证实Fractomer有能力促进与修复和修复相关的细胞渗透和血管形成
重塑,而不是疤痕形成和纤维化。最后,在小鼠腹部脂肪移植模型中,Fractomer
使脂肪移植物的形态、定位和结构保留长达三个月。在第二阶段,我们将
通过以下方式继续Fractomer的商业开发:1)规模化制造;2)完成必要的
FDA要求的生物兼容性和毒性研究之前的研究设备豁免状态
临床测试;以及3)在猪乳房脂肪垫修复模型中测试材料的安全性和有效性。
英文摘要
Project Summary
The objective of this proposal is to further develop a new restorative tissue matrix which Phase I studies indicate
is capable of expanding the utility of autologous fat grafting in breast reconstructive surgery. This objective is
motivated by the need to improve the accessibility and safety of breast reconstruction for cancer patients. Breast
implants dominate the field as they are easy to place and provide a defined shape. However, growing concerns
over the long-term impact of implants with regards to capsular contracture, breast implant illness (BII) and breast
implant associated anaplastic large cell lymphoma (BIA-ALCL) are driving many patients to seek other options.
Tissue flap procedures effectively deliver large sections of fat to the defect; however, these procedures are
complex, expensive, and not widely available to all patients. The long-term outcomes of successful tissue flaps
are favorable but associated with significant investment in time, money, bodily scars, and effort. A third option
is autologous fat, which can also be transferred as a graft using only liposuction and small injection cannulas as
an outpatient procedure. Despite its potential, many surgeons feel limited in their capabilities when using fat
grafts as: (1) harvesting fat with liposuction destroys its structural matrix, resulting in a shapeless slurry, and (2)
many patients simply do not have enough fat to donate. To date, the technical and surgical barriers to using fat
grafting for definitive breast reconstruction have not been solved. While attempts have been made to improve
graft success rates by combining tissue with synthetic polymers or decellularized tissue, these attempts have
shown minimal success due to a lack of intrinsic bioactivity, high cost, or long processing times. Recombinant
protein polymers are an unexplored but promising alternative, whereby mimics of naturally occurring extracellular
matrix proteins can be synthesized at high yield with molecular level control of their properties. Motivated by this
clear clinical need, this proposal seeks to advance commercialization of a recently developed innovative
biomatrix —Fractomer. Fractomers are artificial proteins designed to mimic soft tissue that can be co-injected
with fat to expand volume, increase long-term stability, and improve fat shape by allowing tissue ingrowth and
blood vessel formation. The Phase I program focused on Fractomer’s interaction with lipoaspirate to determine
biomechanical and thermal response properties ideally suited to a tissue repair matrix. In vivo studies
demonstrated Fractomer’s ability to promote cellular infiltration and vascularization associated with repair and
remodeling, as opposed to scar formation and fibrosis. Finally, in a murine flank fat grafting model, Fractomer
enabled the retention of form, localization, and structure of fat grafts up to three months. During Phase II we will
continue commercial development of Fractomer by: 1) scaling manufacturing; 2) completing necessary
biocompatibility and toxicity studies as required by the FDA for Investigational Device Exemption status prior to
clinical testing; and 3) testing the material’s safety and efficacy in a porcine model of mammary fat pad repair.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A recombinant elastin skin substitute for the treatment of burns
-
批准号:10601801
-
项目类别:
-
资助金额:$28.24万
-
财政年份:2023
-
负责人:Stefan Roberts
-
依托单位:
Fully defined matrices for organoid culture
-
批准号:10257860
-
项目类别:
-
资助金额:$29.08万
-
财政年份:2021
-
负责人:Stefan Roberts
-
依托单位:
A recombinant matrix to improve autologous tissue grafts
-
批准号:10384086
-
项目类别:
-
资助金额:$93.68万
-
财政年份:2019
-
负责人:Stefan Roberts
-
依托单位:
Functional analysis of the WT1-BASP1 transcriptional repressor complex
-
批准号:8246052
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2012
-
负责人:Stefan Roberts
-
依托单位:
海外基金